Approved by the Medicines and Healthcare products Regulatory Agency (MHRA), the injectable will cut down on immunotherapy ...

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Van Andel Institute scientists and collaborators have discovered a potential treatment target that may re-energize ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...